Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ertugliflozin for Functional Mitral Regurgitation
NCT04231331Phase 3Completed
- Sponsor
- Asan Medical Center
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial comparing Ertugliflozin with Placebo (2 arms). Primary endpoint: Change of Effective Regurgitant Orifice Area at 12 months. Started Nov 2020; status: completed.
02
Drugs
ertugliflozin
Beyond the preview
Go deeper on NCT04231331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231331.